The LIFT-AD Trial is evaluating the safety and effectiveness of an investigational medication (a medication not approved for routine clinical use) for people with mild to moderate Alzheimer’s disease.
The trial involves 9 clinic visits over the course of up to 30 weeks. There is no cost to participate in this study. All study medication and office visits are included at no cost to participants.
Participants are randomly assigned to a treatment group. They receive either the investigational medication or a placebo (a substance that looks like the investigational medication but contains no active ingredients), which is administered through a subcutaneous injection (a small injection under the skin) at home using provided prefilled syringes.